The clinical performance is complex and often involves multiple systemic burdens. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of the MASS model requires individualized development, usually including multidimensional management, such as drug therapy, rehabilitation interventions, and regular follow-up visits. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immunodeficiency disorders that were previously difficult to treat have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored during the treatment process, and timely adjusted according to the changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of MASS models. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.